Clinical Trial Detail

NCT ID NCT02359565
Title Pembrolizumab in Treating Younger Patients With Recurrent, Progressive, or Refractory High-Grade Gliomas or Diffuse Intrinsic Pontine Gliomas
Recruitment Recruiting
Gender both
Phase Phase I
Variant Requirements No
Sponsors National Cancer Institute (NCI)
Indications

malignant glioma

Therapies

Pembrolizumab

Age Groups: adult child

No variant requirements are available.